Drug Combo Proves Powerful Against Lung Cancer Islip NY

A two-drug combination treatment in Islip proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Niti DuBe
(516) 932-6007
688 Old Country Rd
Plainview, NY
STEVEN SUGARMAN, MD
(646) 227-3813
650 Commack Road
Commack, NY
Umme Habiba Begum, MD
315-798-1832
Suny At Stony Brook/Univ Hosp
Stony Brook, NY
Bong Soon Kim, MD
631-344-7705
15th Fl Rm 040,
Stony Brook, NY
Tiffany Troso-Sandoval, MD
631-623-4100
650 Commack Rd
Commack, NY
Suresh K Joshi
(516) 520-9800
3601 Hempstead Tpke Ste 405
Levittown, NY
MARK LIPSHUTZ, MD
(631) 666-6752
24 E Main Street
Bay Shore, NY
Li Ge, MD
Huntington Station, NY
John Stephen Kovach, MD
631-444-9340
7547 Suny
Stony Brook, NY
Birjis Akhun, MD
516-425-2280
180 E Pulaski Rd
Huntington Station, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Hormone Therapy for Lung Cancer Islip NY
Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found. The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.
- Side Effect Of Chemotherapy Drugs Islip NY
- Exercise for Breast Cancer Survival Islip NY
- Exercise for Prostate Cancer Islip NY
- Risks for Childhood Cancer Survivors Islip NY
- Genetic Clues for Skin Cancer Therapies Islip NY
- Fungal Infection Treatments Islip NY
- Hormone Therapy for Breast Cancer Islip NY
- Delayed Prostate Cancer Therapy Islip NY